GUSHENGTANG (02273) rose nearly 4%. As of press time, the stock gained 3.73% to HK$32.22, with a turnover of HK$43.0189 million.

On the news front, GUSHENGTANG released its interim results for 2025 at midday, reporting revenue of RMB 1.495 billion, representing a 9.52% year-on-year increase. EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) reached approximately RMB 270 million, up 37.3% year-on-year. Profit attributable to shareholders totaled RMB 152 million, surging 41.9% year-on-year. The company proposed an interim dividend of HK$0.35 per share, compared to HK$0.13 in the same period last year.

The announcement stated that the revenue increase was primarily due to higher income generated from providing medical and healthcare solutions.

Additionally, GUSHENGTANG announced that its board of directors has resolved to exercise the repurchase mandate to buy back shares in the open market at appropriate times, with a maximum total consideration of HK$300 million. The company will fund this using its internal resources. The company will subsequently cancel or hold the repurchased shares as treasury stock.

Under the repurchase mandate, directors may buy back up to 23.6965 million company shares, representing 10% of the total issued shares as of June 20, 2025.